Rossix.blue.jpg
Home Products Services About Us Contact
img_8304.jpg

Hemostasis Research

Take advantage of Rossix know how in your research and product development.

Phospholipid Emulsions

Our highly stable phospholipid emulsions are suitable for use in analyses related to procoagulant and anticoagulant pathways.

Chromogenic Kits

Learn more about our Chromogenic Kits.

References

References

Rossix products are used by well renowned academic scientists as well as by leading pharmaceutical companies.

We perform contract analysis and method development on a regular basis for some of the major global pharmaceutical companies.

For enquiries regarding our track record and/or which types of projects we may handle please contact us directly and we will give you more detailed information.

Scientific publications

The section below presents references in which Rossix products have been utilised as well as publications from Rossix.

Phospholipids

For a reference list on our phospholipids:


Rox Factor IX

Jianming Liu et al

AstraZeneca R&D Mölndal

Protein J. 2014; 33(2): 174-183

Improved Expression of Recombinant Human Factor IX by Co-expression of GGCX, VKOR and Furin.


Rox FIX-A (determination of Factor IXa activity)

Peter L Turecek et al.

Expert Review of Clinical Pharmacology, March 2015, Vol. 8, No. 2 Pages 163 - 177

Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.

Gerald Schrenk et al. Baxter Innovations GmbH, Vienna, Austria.

Does the factor IXa content of factor IX products impact function, safety and efficacy.

Poster Presented at the Bari International Conference (8th BIC) 2014 in Bari, Italy, Oct 3-5, 2014

H. V. Wilmot, J.Hogwood and E.Gray

Haemostasis Section, Biotherapeutics Group, National Institute for Biological Standards and Control, Potters Bar, UK

Haemophilia (2014), 20, 891-897

Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.

Böhm E, Dockal M, Pilz J, Schrenk G, Varadi K, Scheillinger F.

Superiority of the chromogenic assay specific for activated factor IX (FIXa) over the non-activated partial thromboplastin time (NAPTT) clotting assay in detecting FIXa in recombinant FIX (rFIX) preparations.

XXIV ISTH Congress 2013; Poster PB1.39-6.


Rox Prothrombin

Lövgren A

Recombinant snake venom prothrombin activators.           

Bioengineered  4 (3), 153-157 (2013)

Brenden N, Madeyski-Bengtson K, Martinsson K, Svärd R, Albery-Larsdotter S, Granath B, Lundgren H, Lövgren A

A triple-transgenic immunotolerant mouse model.

J Pharm Sci  102 (3), 1116-1124 (2013).


Other

S. ROSÉN

Chromogenic methods in coagulation diagnostics.

Hämostaseologie Aug;25 (3), 259-266 (2005)

News

2016-06-22 Publication in collaboration with NovoNordisk

Rosén P, Rosén S, Ezban M, Persson E.

Overestimation of N-glycoPEGylated factor IX activity in one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.

J Thromb Haemost 2016; 14: 1420-7.

 

2016-05-23 Steffen Rosén, Rossix will hold a presentation at the SSC meeting in Montpellier.

Title : New Tools to Study Contact Activation
Session : Factor XI and the Contact System
Room : Barthez
Date : 27-05-2016

 

2016-05-23 Pia Bryngelhed, Rossix will present a poster at the SSC meeting in Montpellier.

Poster FVIII-49:

Application of Rox Factor IX on the ACL TOP 700

 

2015-04-13 Publication in collaboration with AstraZeneca

Ann Lövgren et al. Blood Coagulation and Fibrinolysis, Characterization of thrombin derived from 

human recombinant prothrombin.

Open access: click here

 

2014-11-13 ECAT meeting 2014 - Leiden, NL

Steffen Rosén, Rossix held a presentation titled

How to measure low levels of Factor VIII and IX

 

2014-06-18  Rox Factor IX - CE

The Rox Factor IX kit for determination of Factor IX activity is approved for In Vitro Diagnostic Use in Europe.

Learn more >>

 

Search